Premium
All‐ trans ‐ retinoic acid shifts Th1 towards Th2 cell differentiation by targeting NFAT1 signalling to ameliorate immune‐mediated aplastic anaemia
Author(s) -
Tang Dabin,
Liu Shengli,
Sun Huiying,
Qin Xia,
Zhou Neng,
Zheng Weiwei,
Zhang Mengyi,
Zhou Hang,
Tuersunayi Abudureheman,
Duan Caiwen,
Chen Jing
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16871
Subject(s) - retinoic acid , t cell , immunology , immune system , haematopoiesis , aplastic anemia , stem cell , ciclosporin , cancer research , medicine , biology , bone marrow , transplantation , microbiology and biotechnology , cell culture , genetics
Summary Severe acquired aplastic anaemia (AA) is a serious disease characterised by autoreactive T cells attacking haematopoietic stem cells, leading to marrow hypoplasia and pancytopenia. Immunosuppressive therapy combined with antithymocyte globulin and ciclosporin can rescue most patients with AA. However, the relapse after ciclosporin withdrawal and the severe side effects of long‐term ciclosporin administration remain unresolved. As such, new strategies should be developed to supplement current therapeutics and treat AA. In this study, the possibility of all‐ trans‐ retinoic acid (ATRA) as an alternative AA treatment was tested by using an immune‐mediated mouse model of AA. Results revealed that ATRA inhibited T‐cell proliferation, activation and effector function. It also restrained the Fas/Fasl pathway, shifted Th1 towards Th2 cell development, rebalanced T‐cell subsets at a relatively high level and corrected the Th1/Th2 ratio by targeting NFAT1 signalling. In addition, ATRA inhibited Th17 cell differentiation and promoted regulatory T‐cell development. Therefore, ATRA was an effective agent to improve AA treatment outcomes.